• Cardiogreen (Indocyanine Green): Applied Protocols & PDT Ins

  2026-05-22

  Cardiogreen (Indocyanine Green) empowers high-precision vascular diagnostics and advanced photodynamic therapy, offering robust reliability in both clinical and research workflows. Explore stepwise protocols, troubleshooting guidance, and new frontiers in immuno-oncology, with APExBIO’s high-purity dye as your foundation.

• Translational Impact of SD 169 in p38 MAPK Pathway Research

  2026-05-22

  This thought-leadership article explores the mechanistic advances and strategic value of SD 169 (indole-5-carboxamide) as a dual-action p38 MAPK inhibitor. Bridging recent structural insights with practical workflow guidance, it highlights how SD 169 offers new precision for inflammation, neuroregeneration, and type 1 diabetes research—outlining evidence-based protocols, translational implications, and future directions for kinase inhibitor design.

• Recombinant Human Growth Hormone: Advanced Workflows & Troub

  2026-05-21

  Leverage APExBIO’s Recombinant Human Growth Hormone (GH) for highly reproducible growth hormone signaling studies and robust cell proliferation assays. This guide translates breakthrough findings on the IGFBP2–THBS1 axis into actionable workflows, protocol enhancements, and troubleshooting insights for pituitary growth hormone research.

• IMPDH Inhibition Disrupts PEDV Replication via Host Nucleoti

  2026-05-21

  This study identifies inosine monophosphate dehydrogenase (IMPDH) as a critical host factor for porcine epidemic diarrhea virus (PEDV) replication by demonstrating that both genetic and pharmacological inhibition—specifically with Merimepodib (VX-497)—impair viral RNA synthesis. The findings reveal how PEDV manipulates host nucleotide biosynthesis and highlight IMPDH as a promising target for antiviral intervention.

• CDC42 Drives HBV Entry via NTCP Trafficking and Macropinocyt

  2026-05-20

  This study uncovers how the small GTPase CDC42 enables hepatitis B virus (HBV) entry into hepatocytes by promoting NTCP translocation to the plasma membrane and facilitating macropinocytosis. The findings reveal a dual mechanism for HBV uptake, suggesting new antiviral intervention points and offering insights for researchers studying viral entry pathways.

• ATM Inhibition Promotes Macropinocytosis: New Metabolic Vuln

  2026-05-20

  This study demonstrates that ATM kinase inhibition triggers increased macropinocytosis, allowing cancer cells to adapt metabolically and survive in nutrient-poor environments. The findings reveal a previously unappreciated metabolic vulnerability in ATM-inhibited tumors, with implications for the design of combinatorial cancer therapies targeting both DNA damage response and nutrient scavenging pathways.

• Kanamycin Sulfate: Water-Soluble Antibiotic for Precision Mi

  2026-05-19

  Kanamycin Sulfate enables reliable bacterial selection and advanced resistance studies thanks to its high water solubility and robust protein synthesis inhibition. This guide unpacks validated workflows, troubleshooting strategies, and comparative insights that empower rigorous, reproducible research outcomes.

• Alpha-2 Receptor Control of Itch and Pain via LC Noradrenerg

  2026-05-19

  This study reveals that the descending noradrenergic pathway from the locus coeruleus modulates itch and pain in an antagonistic manner via α2 adrenergic receptors. These findings clarify the central mechanisms underlying the balance of itch and pain and provide actionable insights for chemogenetic modulation in neuroscience research.

• Amitriptyline HCl: Workflow Guidance for Neuropharmacology R

  2026-05-18

  Amitriptyline HCl facilitates consistent neurotransmitter receptor modulation in neuropharmacology, mood disorder, and neurodegenerative disease research. Researchers should use this compound when robust, multi-receptor inhibition is required, but avoid speculative or long-term solution storage beyond recommended protocols.

• Fasudil (HA-1077) HCl: Optimizing ROCK Inhibition Workflows

  2026-05-18

  Fasudil (HA-1077) HCl, a selective ROCK inhibitor from APExBIO, empowers researchers with precise, reliable control over Rho/ROCK signaling in cancer and disease models. This guide details practical workflows, protocol refinements, and troubleshooting strategies to maximize experimental impact—plus actionable insight from recent Hippo pathway research.

• IWR-1-endo: Precision Wnt Signaling Inhibitor for Cancer Res

  2026-05-17

  IWR-1-endo, a potent Wnt signaling inhibitor from APExBIO, empowers researchers to dissect Wnt/β-catenin pathways in colorectal cancer and regenerative biology. This guide details advanced workflows, troubleshooting tips, and practical insights for maximizing assay fidelity and reproducibility.

• Palonosetron Hydrochloride in CINV/RINV: Updated Clinical In

  2026-05-16

  This article reviews the recent update by Fabi & Malaguti (2013) on palonosetron hydrochloride, focusing on its distinctive pharmacological properties, clinical trial outcomes, and positioning in antiemetic guidelines for chemotherapy- and radiotherapy-induced nausea and vomiting. The findings highlight palonosetron’s superior efficacy for delayed emesis and its integration into evolving clinical protocols.

• Streptavidin-FITC: Precision Fluorescence for Biotinylated M

  2026-05-15

  Discover the scientific fundamentals and advanced applications of Streptavidin-FITC in sensitive biotin detection, with a focus on assay optimization and practical insights. Learn how fluorescein isothiocyanate conjugated streptavidin enables superior workflow performance across immunohistochemistry, flow cytometry, and cutting-edge nanoparticle tracking.

• Cefiderocol Activity Against Resistant P. aeruginosa & Acine

  2026-05-15

  This study systematically evaluates the in vitro efficacy of cefiderocol against a large European collection of Pseudomonas aeruginosa and Acinetobacter spp., including strains resistant to meropenem and several β-lactam/β-lactamase inhibitor combinations. The findings inform susceptibility-guided therapeutic decisions for challenging Gram-negative infections.

• ERAD-Engaging Chimeras Enable Degradation of Transmembrane P

  2026-05-14

  Song et al. report a platform that harnesses ER-associated degradation (ERAD) to achieve potent and selective removal of transmembrane (TM) proteins, overcoming longstanding barriers of targeted protein degradation. This innovation enables new opportunities for precision modulation of membrane protein function, with implications for immunology and cancer research.

16910 records 1/1128 page Next 12345 下5页 Last page